Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas-Reference-Cited by-同舟云学术

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Published:2005-06-01 Issue:5 Volume:7 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

von Minckwitz Gunter,Harder Sebastian,Hövelmann Sascha,Jäger Elke,Al-Batran Salah-Eddin,Loibl Sibylle,Atmaca Akin,Cimpoiasu Christian,Neumann Antje,Abera Aklil,Knuth Alexander,Kaufmann Manfred,Jäger Dirk,Maurer Alexander B,Wels Winfried S

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1186/bcr1264/fulltext.html

Reference35 articles.

1. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093/emboj/19.13.3159.

2. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.

3. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19: 6550-6565. 10.1038/sj.onc.1204082.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.

5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 719-726. 10.1200/JCO.20.3.719.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review;Human Immunology;2024-09

2. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH;Journal of Translational Medicine;2023-08-25

3. New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery;Therapeutic Delivery;2023-01

4. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs;Cancers;2022-09-19

5. Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents;Molecules;2022-06-14